Last reviewed · How we verify
Vfend (voriconazole) tablet
Voriconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.
Voriconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Invasive aspergillosis, Esophageal candidiasis, Candidemia in non-neutropenic patients.
At a glance
| Generic name | Vfend (voriconazole) tablet |
|---|---|
| Also known as | Oral |
| Sponsor | Seoul National University Hospital |
| Drug class | Triazole antifungal |
| Target | Cytochrome P450 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
By blocking a key enzyme in the ergosterol biosynthesis pathway, voriconazole causes depletion of ergosterol and accumulation of toxic sterol precursors, leading to fungal cell membrane instability and cell death. This mechanism is selective for fungi because the target enzyme and ergosterol-dependent membrane structure are unique to fungal cells, making it effective against a broad spectrum of fungal pathogens.
Approved indications
- Invasive aspergillosis
- Esophageal candidiasis
- Candidemia in non-neutropenic patients
- Serious Candida infections of the skin and infections of the abdomen, kidney, bladder wall, and wounds
- Scedosporium apiorum and Fusarium species infections in immunocompromised patients
Common side effects
- Visual disturbances (blurred vision, photopsia)
- Hepatotoxicity (elevated liver enzymes)
- Rash
- Photosensitivity
- Headache
- Hallucinations
- QT prolongation
Key clinical trials
- Study on the Drug Interaction Between Buagafuran and Voriconazole (PHASE1)
- Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects (PHASE1)
- Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections (PHASE2)
- Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes (PHASE1)
- Study of Biomarker-Based Treatment of Acute Myeloid Leukemia (PHASE1, PHASE2)
- Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies (PHASE1)
- Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (PHASE1, PHASE2)
- Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vfend (voriconazole) tablet CI brief — competitive landscape report
- Vfend (voriconazole) tablet updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI